Quantum Genesis AI Corp.

Quantumzyme Corp. is a biotransformation company that develops engineered enzymes focused on clean and green chemistry. The company designs biocatalysts to optimize active pharmaceutical ingredient production by replacing legacy chemical processes that use hazardous materials with environmentally sustainable alternatives. Its initial engineered enzyme product serves the pharmaceutical production of generic ibuprofen. Quantumzyme intends to license its technology to major pharmaceutical firms and active pharmaceutical ingredient manufacturers, while partnering with third-party organizations for large-scale manufacturing and distribution.

The company operates with a single employee, who serves as President and director. Quantumzyme does not own real property or laboratory equipment; instead, it maintains administrative operations in a shared office space and conducts research and development activities at an off-site laboratory facility. The company's business model relies on intellectual property, technical expertise, and collaborative partnerships rather than extensive internal physical infrastructure. The provided text does not state the city, state, or country of its headquarters.

Summary of the business section of Quantum Genesis AI's latest annual report, written by StockData.